Dosage form for treating cyclothymia
First Claim
Patent Images
1. A subglossal dosage form for administering tandospirone to the subglossal tandospirone receptors of a patient in need of tandospirone therapy, wherein the subglossal dosage form comprises:
- (a) a wall comprising a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, and cellulose triacetate which wall surrounds;
(b) an internal lumen;
(c) an exit passageway in the wall that connects the subglossal environment with the internal lumen;
(d) a push composition in the lumen, comprising an osmotically fluid-activated agent that, in the presence of subglossal fluid that enters the lumen, increases in volume and thereby occupies space in the lumen; and
wherein the subglossal dosage form is characterized by;
(e) a subglossal composition comprising 1 mg to 750 mg of tandospirone, a poly(oxyethylene) comprising a 1.75×
105 to 2.25×
105 molecular weight and a poly(oxyethylene) comprising a 2.50×
105 to 3.25×
105 molecular weight, which subglossal composition when administered to the patient provides tandospirone for treating depression, single and bipolar depression;
depression with and without melancholia, and cyclothymia characterized by lively and depressed moods.
2 Assignments
0 Petitions
Accused Products
Abstract
A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.
-
Citations
1 Claim
-
1. A subglossal dosage form for administering tandospirone to the subglossal tandospirone receptors of a patient in need of tandospirone therapy, wherein the subglossal dosage form comprises:
-
(a) a wall comprising a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, and cellulose triacetate which wall surrounds; (b) an internal lumen; (c) an exit passageway in the wall that connects the subglossal environment with the internal lumen; (d) a push composition in the lumen, comprising an osmotically fluid-activated agent that, in the presence of subglossal fluid that enters the lumen, increases in volume and thereby occupies space in the lumen; and
wherein the subglossal dosage form is characterized by;(e) a subglossal composition comprising 1 mg to 750 mg of tandospirone, a poly(oxyethylene) comprising a 1.75×
105 to 2.25×
105 molecular weight and a poly(oxyethylene) comprising a 2.50×
105 to 3.25×
105 molecular weight, which subglossal composition when administered to the patient provides tandospirone for treating depression, single and bipolar depression;
depression with and without melancholia, and cyclothymia characterized by lively and depressed moods.
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeEncinal Pharmaceutical Investments, LLC
-
Original AssigneeALZA Corporation (Johnson & Johnson)
-
InventorsAyer, Atul D., Ridzon, Dana
-
Primary Examiner(s)Page, Thurman K.
-
Assistant Examiner(s)BROUILLETTE, D GABRIELLE
-
Application NumberUS07/942,899Time in Patent Office376 DaysField of Search424/473, 424/468US Class Current424/473CPC Class CodesA61K 31/495 having six-membered rings w...A61K 31/496 Non-condensed piperazines c...A61K 31/505 Pyrimidines; Hydrogenated p...A61K 9/0004 Osmotic delivery systems; S...
